Neurolens

What Neurolens does

Neurolens is a privately held neurotechnology company operating in the prescription eyewear sector, founded in 2012 and headquartered in Coppell, Texas (Delaware corporation). The company designs and markets prescription lenses that incorporate a contoured prism intended to bring the eyes into alignment, targeting patients whose visual misalignment contributes to symptoms such as headaches, eye strain, and related conditions. Its core product is a patented contoured-prism lens system sold exclusively through licensed eye-care practitioners, supported by a clinical measurement and prescribing protocol used by optometrists.

Neurolens operates a business-to-business-to-consumer model: it does not sell directly to end users but rather equips and supplies a network of prescribing optometrists, who in turn dispense the lenses to patients as part of an eye exam and prescription workflow. Revenue is generated from the sale of these specialty prescription lenses, with replacement cycles on the patient side providing recurring demand. Pricing is not publicly disclosed and there is no direct-to-consumer channel, app, or software offering in the input data. The company is controlled by its executive team and has raised approximately $186 million+ across nine equity and debt rounds from 2014 through 2023, with the most recent being a $45 million growth-capital facility from Trinity Capital in December 2023.

The company is at a commercial scaling stage, evidenced by a 101-250 employee headcount, a dedicated Chief Revenue Officer, and continued capital deployment under non-dilutive debt structures — signals consistent with broader penetration of its ECP channel rather than early clinical validation. Its strategic risk is dependence on a single product category (contoured prism lenses) and a single channel (optometric prescribing), while its defensibility rests on proprietary lens technology, prescriber training and integration, and the recurring-replacement nature of prescription eyewear.

Name

Neurolens

Legal name

Neurolens, Inc.

Website

https://neurolenses.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Neurolens is a private, Coppell-based neurotechnology eyewear company that designs prescription lenses with a proprietary contoured prism to correct eye misalignment, sold to patients through a network of licensed optometrists.

Ownership category

akta.pro rank

Product category

Ophthalmic prescription lenses

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD)

akta.pro secondary industry

Optometry Clinics (Primary Eye Care) (HLAKAKAB)

Keywords

• Prescription ophthalmic lenses
• Contoured prism lenses
• Binocular vision correction
• Eye alignment eyewear
• Neurotechnology optometry

Headquarters

HQ city

Coppell

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel

Core offering

Neurolens designs and manufactures prescription ophthalmic lenses that incorporate a contoured prism to bring the eyes into alignment, addressing binocular vision dysfunction. The lenses are dispensed through eye care professionals and are prescribed using the company's clinical measurement system that quantifies eye misalignment at near and distance.

Differentiator

Problem solved

Functional benefit

Products and services

• Neurolens contoured prism prescription lenses

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• EssilorLuxottica: World's largest ophthalmic lens and eyewear company, producing prescription lenses, frames, and retail optical brands. Highly comparable as a vertically integrated lens maker with far greater scale, distribution, and ability to bundle competing alignment technologies.
• Bausch + Lomb: Diversified eye-health company with a presence in ophthalmic pharmaceuticals, contact lenses, and lens care. Comparable as a broader ophthalmic player with adjacent vision-care offerings and strong eyecare channel relationships.
• CooperVision: Major contact lens manufacturer serving eyecare professionals globally. Comparable as a vision-care company whose products are dispensed through the same optometrist channel as Neurolens.
• Johnson & Johnson Vision: Ophthalmic division of J&J covering contact lenses, surgical vision, and dry-eye treatments. Comparable as a large vision-care incumbent with overlapping practitioner relationships and category breadth.
• Safilo Group: Global eyewear manufacturer and distributor of optical frames and sunglasses. Comparable as a broad eyewear incumbent whose products are sold through the same eyecare channel and could extend into specialty lenses.

Direct peers

• HOYA Vision Care: Major manufacturer of ophthalmic lenses, including progressive and specialty designs, sold through eyecare professionals globally. Directly comparable as a prescription-lens competitor with overlapping channel and product positioning.
• Carl Zeiss Vision (ZEISS): Premium ophthalmic lens manufacturer offering customized single-vision, progressive, and office lenses dispensed through optometrists. Comparable as a high-end specialty lens maker competing for the same practitioner-prescribed prescription lens market.
• Shamir Optical Industry: Specialist ophthalmic lens maker known for progressive and occupational lens designs sold through independent ECPs. Comparable as a technology-forward lens company with a similar go-to-market through eyecare professionals.

Others

• Mitsui Chemicals (Ophthalmic & Vision Care): Materials supplier producing high-index lens materials and ophthalmic-grade plastics. Comparable as an upstream input provider in the ophthalmic lens value chain, with potential integration implications for specialty lens makers.

Emerging players

• Warby Parker: Direct-to-consumer eyewear brand offering prescription glasses and contact lenses, increasingly expanding in-store exam capacity. Comparable as an emerging player reshaping how prescription eyewear is sold and potentially competing for patient attention and practitioner relationships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/18111156

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurolens